is adjuvant chemotherapy in egfr mutated nsclc still required?
Published 1 year ago • 130 plays • Length 3:52Download video MP4
Download video MP3
Similar videos
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
2:20
osimertinib with chemotherapy in egfr-mutated nsclc | nejm
-
1:42
adaura: the benefit of adjuvant osimertinib
-
1:50
consolidation therapy for unresectable stage iii egfr-mutant nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
0:43
developments in the management of egfr-mutated nsclc
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
1:04
molecular testing in egfr mutant driven nsclc
-
1:52
is adjuvant immunotherapy necessary in non-small cell lung cancer?
-
1:33
neoadjuvant egfr tki trials in nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
14:30
adjuvant therapy for egfr mutant nsclc
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
3:19
adjuvant osimertinib in resected egfr-mutated nsclc
-
0:50
implications of the ictan trial of icotinib for resected egfr-mutated stage ii-iiia nsclc